A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies
Sponsor: Genentech, Inc.
This PHASE2 trial investigates Peripheral Neuropathy and is currently ongoing. Genentech, Inc. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- National Center for Research Resources (NCRR)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.